Cogent Biosciences, Inc (COGT) insider trading
Every open-market stock purchase and sale by Cogent Biosciences, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $382M over the last 12 months (6 sales). No open-market buys.
- Last insider buy: Fairmount Funds Management LLC (Director), $25M, 15 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $382M (6 sales). Last close $31.02 on Jun 4, 2026.
Recent COGT insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 9, 2026 | Todd Shegog (Insider) | Bought (not open market) | — |
| Jun 9, 2026 | Christopher W. Cain (Insider) | Bought (not open market) | — |
| Jun 9, 2026 | Karen Jean Ferrante (Insider) | Bought (not open market) | — |
| Jun 9, 2026 | Peter Evan Harwin (Insider) | Bought (not open market) | — |
| Jun 9, 2026 | Matthew Ros (Insider) | Bought (not open market) | — |
| Jun 9, 2026 | Arlene Morris (Insider) | Bought (not open market) | — |
| May 19, 2026 | Andrew R Robbins (CEO) | Bought (not open market) | — |
| Apr 1, 2026 | Karen Jean Ferrante (Insider) | Bought (not open market) | — |
| Mar 31, 2026 | Fairmount Funds Management LLC (Director) | Sold | $243M |
| Mar 31, 2026 | Fairmount Funds Management LLC (Director) | Bought (not open market) | — |
| Mar 31, 2026 | Fairmount Funds Management LLC (Director) | Bought (not open market) | — |
| Jan 22, 2026 | Fairmount Funds Management LLC (Director) | Sold | $127M |
| Jan 1, 2026 | Karen Jean Ferrante (Insider) | Bought (not open market) | — |
| Dec 26, 2025 | John Edward Robinson (C-suite exec) | Sold | $3.5M |
| Dec 26, 2025 | Jessica Sachs (C-suite exec) | Sold | $3.2M |
| Dec 26, 2025 | John L. Green (CFO) | Sold | $3M |
| Dec 26, 2025 | Evan Kearns (C-suite exec) | Sold | $2.5M |
| Dec 17, 2025 | Andrew R Robbins (CEO) | Sold (not open market) | $14.5M |
| Dec 17, 2025 | Jessica Sachs (C-suite exec) | Sold (not open market) | $6.1M |
| Dec 17, 2025 | John L. Green (CFO) | Sold (not open market) | $5.7M |
| Dec 17, 2025 | John Edward Robinson (C-suite exec) | Sold (not open market) | $5.5M |
| Dec 17, 2025 | Evan Kearns (C-suite exec) | Sold (not open market) | $5M |
| Dec 17, 2025 | Cole Pinnow (C-suite exec) | Sold (not open market) | $3.7M |
| Dec 17, 2025 | Evan Kearns (C-suite exec) | Bought (not open market) | — |
| Dec 17, 2025 | Jessica Sachs (C-suite exec) | Bought (not open market) | — |
Who's trading COGT
- Todd Shegog, Insider: other filings, last Jun 9, 2026
- Karen Jean Ferrante, Insider: other filings, last Jun 9, 2026
- Peter Evan Harwin, Insider: other filings, last Jun 9, 2026
- Arlene Morris, Insider: other filings, last Jun 9, 2026
- Matthew Ros, Insider: other filings, last Jun 9, 2026
- Christopher W. Cain, Insider: other filings, last Jun 9, 2026
- Andrew R Robbins, CEO: other filings, last May 19, 2026
- Fairmount Funds Management LLC, Insider: sold $370M (2 sales), last Mar 31, 2026
- Jessica Sachs, C-suite exec: sold $3.2M (1 sale), last Dec 26, 2025
- John L. Green, CFO: sold $3M (1 sale), last Dec 26, 2025
- John Edward Robinson, C-suite exec: sold $3.5M (1 sale), last Dec 26, 2025
- Evan Kearns, C-suite exec: sold $2.5M (1 sale), last Dec 26, 2025
- Cole Pinnow, C-suite exec: other filings, last Dec 17, 2025
Get free alerts when an insider at Cogent Biosciences, Inc files a new trade →